Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer (Q36174218)

12 August 2017

Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer (English)

1 reference

12 August 2017

Qiao Li

1

1 reference

12 August 2017

Takekazu Iuchi

series ordinal

2

1 reference

12 August 2017

Maria N Jure-Kunkel

series ordinal

3

1 reference

12 August 2017

Alfred E Chang

series ordinal

4

1 reference

12 August 2017

language of work or name

English

0 references

publication date

20 November 2007

1 reference

International Journal of Biological Sciences

12 August 2017

1 reference

12 August 2017

3

1 reference

12 August 2017

7

1 reference

12 August 2017

455-462

1 reference

Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8 T cells

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

IL-21 induces the functional maturation of murine NK cells

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

Cutting edge: Expression of functional CD137 receptor by dendritic cells

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

In vivo stimulation of CD137 broadens primary antiviral CD8 T cell responses

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

Mice with STAT6-targeted gene disruption develop a Th1 response and control cutaneous leishmaniasis.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

Complete regression of large solid tumors using engineered drug-resistant hematopoietic cells and anti-CD137 immunotherapy

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

Role of immature myeloid Gr-1 cells in the development of antitumor immunity

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

Identification of novel IL-4/Stat6-regulated genes in T lymphocytes.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

4-1BB promotes the survival of CD8 T lymphocytes by increasing expression of Bcl-xL and Bfl-1.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4 and CD8 T cells and intratumoral lymphotactin transgene expression.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2096735

Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer

23 September 2018

1 reference

12 December 2020

Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses

1 reference

12 December 2020

4-1BB cross-linking enhances the survival and cell cycle progression of CD4 T lymphocytes

1 reference

12 December 2020

In vivo antitumor activity of interleukin 21 mediated by natural killer cells

1 reference

12 December 2020

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study

1 reference

12 December 2020

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

1 reference

12 December 2020

Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role

1 reference

12 December 2020

Cutting edge: 4-1BB is a bona fide CD8 T cell survival signal

1 reference

12 December 2020

STAT-4 mediated IL-12 signaling pathway is critical for the development of protective immunity in cutaneous leishmaniasis

1 reference

12 December 2020

Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines

1 reference

12 December 2020

Quantitative assessment of human T lymphocytes in RAG2(-/-)gammac(-/-) mice: the impact of ex vivo manipulation on in vivo functionality

1 reference

12 December 2020

Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment

1 reference

12 December 2020

4-1BB costimulation of effector T cells for adoptive immunotherapy of cancer: involvement of Bcl gene family members

1 reference

12 December 2020

CD134 Costimulation Couples the CD137 Pathway to Induce Production of Supereffector CD8 T Cells That Become IL-7 Dependent

1 reference

12 December 2020

The p38 mitogen-activated protein kinase is required for IL-12-induced IFN-gamma expression

1 reference

12 December 2020

Differential clonal expansion of CD4 and CD8 T cells in response to 4-1BB ligation: contribution of 4-1BB during inflammatory responses

1 reference

12 December 2020

4-1BB co-stimulation enhances human CD8( ) T cell priming by augmenting the proliferation and survival of effector CD8( ) T cells

1 reference

12 December 2020

Signaling through NK cell-associated CD137 promotes both helper function for CD8 cytolytic T cells and responsiveness to IL-2 but not cytolytic activity

1 reference

12 December 2020

Polarization effects of 4-1BB during CD28 costimulation in generating tumor-reactive T cells for cancer immunotherapy

1 reference

12 December 2020

Identifiers

DOI

10.7150/IJBS.3.455

1 reference

release_u74pkoek6jge7aulwu54uui7ya

12 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/u74pkoek6jge7aulwu54uui7ya

24 November 2022

mapped directly with Wikidata item

1 reference

12 August 2017

PubMed publication ID

18071585

1 reference